AMPH vs LQDA
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension.
Side-by-side fundamentals
| Metric | AMPH | LQDA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.30 | $87.04 | |
| Market cap as of 2026-07-23 | $864M | $7.7B | |
| P/E as of 2026-07-23 | 10.90 | 347.02 | AMPH lower |
| PEG as of 2026-07-23 | -1.77 | n/a | |
| Net margin as of 2026-07-23 | +11.0% | +7.7% | AMPH higher |
| Gross margin as of 2026-07-23 | +47.3% | +91.8% | LQDA higher |
| Operating margin as of 2026-07-23 | +16.2% | +15.8% | AMPH higher |
| ROE as of 2026-07-23 | +10.2% | +46.8% | LQDA higher |
| ROA as of 2026-07-23 | +4.8% | +7.1% | LQDA higher |
| Debt / equity as of 2026-07-23 | 0.79 | 1.64 | AMPH lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.4% | +1936.7% | LQDA higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +115.0% | LQDA higher |
| Beta as of 2026-07-23 | 0.91 | 0.58 | |
| 1-year return as of 2026-07-22 close | -7.6% | +424.3% | LQDA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.